Neovasc Inc. Current Ratio

Current Ratio of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Ratio growth rates and interactive chart. The current ratio is a liquidity ratio that measures whether a firm has enough resources to meet its short-term obligations. It is calculated as current assets divided by current liabilities. A ratio below 1 indicates potential trouble for a company, as it doesn't have enough current assets to pay for its short-term liabilities. A ratio above 2 is usually considered healthy.


Highlights and Quick Summary

  • Current Ratio for the quarter ending March 31, 2022 was 12.88 (a 16.19% increase compared to previous quarter)
  • Year-over-year quarterly Current Ratio increased by 30.57%
  • Annual Current Ratio for 2021 was 11.08 (a 439.92% increase from previous year)
  • Annual Current Ratio for 2020 was 2.05 (a 277.04% increase from previous year)
  • Annual Current Ratio for 2019 was 0.54 (a -72.79% decrease from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Ratio of Neovasc Inc.

Most recent Current Ratioof NVCN including historical data for past 10 years.

Interactive Chart of Current Ratio of Neovasc Inc.

Neovasc Inc. Current Ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 12.88
2021 11.08 11.16 9.86 12.93 11.08
2020 2.05 2.19 1.67 0.8 2.05
2019 0.54 0.9 1.36 2.61 0.54
2018 2.0 4.3 3.4 0.92 2.0
2017 0.77 0.69 0.74 0.79 0.77
2016 0.85 0.53 14.32 0.85
2015 17.79 25.13 28.84 34.48 17.79
2014 8.05 14.52 11.52 15.3 8.04
2013 3.22 4.63 4.78 4.63 3.22
2012 6.6 2.89 3.66 7.15 6.6
2011 7.87 7.87

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.